HDR Brachytherapy + EBRT + STAD for Prostate Cancer

Loyola University Medical Center, Maywood, IL
Prostate CancerHDR Brachytherapy + EBRT + STAD - Radiation
18 - 99
What conditions do you have?

Study Summary

This trial is testing a treatment for prostate cancer that has come back after prior radiotherapy, which involves the placement of a radioactive material in the affected area of the prostate temporarily, and then is subsequently removed using a minimally invasive technique. Participants will also receive external radiation for 5 weeks targeting the pelvis and giving a higher dose each day to the suspicious lymph nodes on PET scan.

Eligible Conditions
  • Prostate Cancer Recurrence

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1 & 2

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 24 months

24 months
Toxicity rate

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

HDR Brachytherapy + EBRT + STAD
1 of 1

Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: HDR Brachytherapy + EBRT + STAD · No Placebo Group · Phase 1 & 2

HDR Brachytherapy + EBRT + STAD
Experimental Group · 1 Intervention: HDR Brachytherapy + EBRT + STAD · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

Loyola UniversityLead Sponsor
150 Previous Clinical Trials
30,560 Total Patients Enrolled
Abhishek Solanki, MDPrincipal InvestigatorLoyola University Chicago
1 Previous Clinical Trials
50 Total Patients Enrolled

Eligibility Criteria

Age 18 - 99 · Male Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You can participate if you need to undergo radiation therapy for cancer treatment using specific methods like external beam therapy, brachytherapy, or stereotactic body radiotherapy. Additionally, you have specific cancer-related characteristics in your pelvic region and are also eligible for hormonal therapy.

Frequently Asked Questions

Is there still an opportunity to participate in this research endeavor?

"According to the clinicaltrials.gov website, this research endeavour is currently recruiting participants and was initially made public on May 29th 2018 with a recent update transpired in 2020 of that same month." - Anonymous Online Contributor

Unverified Answer

Is the age criteria for this medical trial limited to those over 85 years old?

"This trial is open to participants between 18 and 99 years old. For those under the age of 18, there are 231 different clinical trials available, while 2110 exams can be found for individuals over 65." - Anonymous Online Contributor

Unverified Answer

How many subjects are being monitored for the current clinical investigation?

"Affirmative. The clinical trial registry on clinicaltrials.gov confirms that this experiment, which was first listed in May 2018, is actively recruiting participants. 24 people need to be recruited from one medical centre for the completion of this research project." - Anonymous Online Contributor

Unverified Answer

Who is the ideal candidate for participation in this research project?

"This clinical trial is seeking 24 individuals with [recurrent prostate cancer](https://www.withpower.com/clinical-trials/recurrent-prostate-cancer) aged between 18 and 99. Eligibility criteria include: biopsy-proven adenocarcinoma of the prostate, Mx or M0 stages cT1 to T3a, Nx or N0 status, external beam radiotherapy using photons/protons, definitive brachytherapy, stereotactic body radiotherapy (SBRT), F18-fluciclovine positive pelvic nodes without distal metastasis nor lymph node involvement beyond this area; also a candidate for hormonal therapy plus an ECOG performance score ranging from 0 to 2 on the" - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.